Global Hydroxychloroquine Drugs Market Size, Share, Opportunities, And Trends By Application (Rheumatoid Arthritis, Malaria, Others), By End-User (Hospitals and Clinics, Ambulatory Surgical Centres, Research Labs), And By Geography - Forecasts From 2025 To 2030

Hydroxychloroquine Drugs Market Size

The global hydroxychloroquine drugs market is projected to grow at a CAGR of 2.62%, from US$1.174 billion in 2025 to US$1.336 billion in 2030.

Hydroxychloroquine is an antimalarial drug commonly prescribed for malaria, but also to treat and control autoimmune diseases such as rheumatoid arthritis and lupus. It functions through the inhibition of inflammation and regulation of the immune system to reduce flare-ups of autoimmune disorders and to suppress the growth of the malaria parasite.

Hydroxychloroquine has a good side effect profile overall, but at times it leads to gastrointestinal irritation, and skin eruption, and when used chronically, the toxic effects include retinal damage. It drew significant attention when COVID-19 appeared, though its efficacy has been proven by only a few limited clinical trials. It is indeed a valuable medication for the chronic management of several diseases but must be used carefully and monitored due to potential adverse effects, even when used long-term.

Hydroxychloroquine Drugs Market Growth Drivers:

• The rising prevalence of chronic rheumatoid conditions, malaria, and lupus among individuals is pushing the demand for hydroxychloroquine drugs.

According to the World Health Organization (WHO), there are approximately 150 diseases or more that fall under the category of rheumatic or musculoskeletal conditions that are associated with different degrees of pain and are progressive. They are also referred to as joint diseases, physical disabilities, spinal disorders, and some other conditions; they may be a result of trauma. Rheumatoid Arthritis, which is among one of the conditions under this category is a type of systemic disease that affects the joints, connective tissues, and muscles. It shows a prevalence of about 0.1% to 0.3%, is more common in women and is found majorly in developed countries. It mainly affects individuals between the ages of 20 and 40.

In addition, malaria, which is another disease that is cured by dosing the affected patients, with hydroxychloroquine, is also among the most prevalent diseases in many regions of the world. According to the World Health Organization, malaria is a disease that is caused by the transmission of Plasmodium parasites to humans by the Anopheles mosquito. According to the World Malaria Report 2024, there were 263 million estimated cases of malaria globally in 2023, with an incidence of 60.4 cases per 1000 population at risk. This is an increase of 11 million cases from the previous year and a rise in incidence from 58.6 cases per 1000 population at risk in 2022. Globally, in 2023, the number of deaths was estimated at 597,000, with a mortality rate of 13.7 per 100,000.

Furthermore, according to the statistics presented by the Lupus Foundation of America, about 5 million individuals globally are suffering from some sort of lupus, of which there are an estimated 1.5 million American individuals. Lupus is an increasingly common disease among women of childbearing age. But, children, men, and teenagers are also likely to develop these diseases. The symptoms that are associated with these diseases include pain, high fatigue levels, cognitive loss, physical impairment, and other symptoms. Thus, since these diseases are increasing, there is a surging demand for hydroxychloroquine drugs which is bolstering the market growth over the forecast period.

• Increasing product offerings by major market players is anticipated to fuel market growth.  

With a rise in the number of new products from the market leaders, this hydroxychloroquine market is expected to grow significantly. As pharmaceutical companies extend their product portfolio, they release new formulations, dosages, and delivery modes of hydroxychloroquine, which help reach a more extensive population of patients and fulfill a wider array of medical requirements. For example, combination therapy or sustained-release formulations may better improve the therapeutic efficacy and facilitate the treatment of diseases such as rheumatoid arthritis, lupus, and malaria.

The partnership agreements and donations of hydroxychloroquine drugs to cater to the growing demand for use in research purposes or as possible care for coronavirus by existing and new players in different markets are estimated to lead to increased adoption and propel the market growth further over the forecast period.

Amneal Pharmaceuticals LLC, which is one of the leading pharmaceutical products and solutions companies announced that they are involved persistently in catering to the supply of the hydroxychloroquine drug and have decided to ramp up their operations and accelerate the growth of their hydroxychloroquine supply. The main objective of hits expansion of the manufacturing of hydroxychloroquine tablets is that they are planning to produce them between now and mid-April, and these tablets will be available to all retail and wholesale consumers.

Hydroxychloroquine Drugs Market Geographical Outlook:

• The global Hydroxychloroquine drugs market is segmented into five regions worldwide

Geography-wise, the market of global Hydroxychloroquine drugs is divided into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The hydroxychloroquine drugs market in North America is driven by several key factors. One of the primary drivers is the high prevalence of autoimmune diseases, such as rheumatoid arthritis and lupus, which require long-term management with medications like hydroxychloroquine. Increased awareness and improved diagnostic capabilities for these conditions further boost demand. The advanced healthcare infrastructure in North America ensures that hydroxychloroquine is readily accessible to patients, and research and development efforts continue to explore new uses for the drug, including its role in treating other diseases. In the Asia Pacific region, the demand for hydroxychloroquine is primarily driven by the high burden of malaria, especially in countries like India, Indonesia, and the Philippines, where the drug is a critical component of malaria prevention and treatment strategies.

The increasing awareness about autoimmune diseases within these regions and the improvement of access to health care are key factors driving growth in the hydroxychloroquine market. The drug is relatively affordable, so it is much more accessible within low- and middle-income countries across the region, where chronic diseases and malaria remain important treatment options. Moreover, hydroxychloroquine is frequently issued by government and NGO-led malaria eradication programs as a part of preventive measures, thereby enhancing demand.

Hydroxychloroquine Drugs Market Scope:

Report Metric	Details
Hydroxychloroquine Drugs Market Size in 2025	US$1.174 billion
Hydroxychloroquine Drugs Market Size in 2030	US$1.336 billion
Growth Rate	CAGR of 2.62%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Billion
Segmentation	Application End-user Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Hydroxychloroquine Drugs Market	Novartis AG Sanofi Amneal Pharmaceuticals LLC. Dr. Reddy’s Laboratories McKesson Medical-Surgical Inc.
Customization Scope	Free report customization with purchase

 

The Hydroxychloroquine drugs market is analyzed into the following segments:

• By Application
  • Rheumatoid Arthritis
  • Malaria
  • Others
• By End-User
  • Hospitals and Clinics
  • Ambulatory Surgical Centres
  • Research Labs
• By Geography
  • North America
    • USA
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Rest of the Middle East and Africa
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Taiwan
    • Thailand
    • Indonesia
    • Rest of Asia-Pacific

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base and Forecast Years Timeline

1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY  

2.1. Research Design

2.2. Research Process

3. EXECUTIVE SUMMARY

3.1. Key Findings

3.2. Analyst View

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porter’s Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. The Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY APPLICATION

5.1. Introduction

5.2. Rheumatoid Arthritis

5.3. Malaria

5.4. Others

6. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY END-USER

6.1. Introduction

6.2. Hospitals and Clinics

6.3. Ambulatory Surgical Centres

6.4. Research Labs

7. GLOBAL HYDROXYCHLOROQUINE DRUGS MARKET BY GEOGRAPHY

7.1. Global Overview

7.2. North America

7.2.1. United States

7.2.2. Canada

7.2.3. Mexico

7.3. South America

7.3.1. Brazil

7.3.2. Argentina

7.3.3. Rest of South America

7.4. Europe

7.4.1. United Kingdom

7.4.2. Germany

7.4.3. France

7.4.4. Italy

7.4.5. Spain

7.4.6. Rest of Europe

7.5. Middle East and Africa

7.5.1. Saudi Arabia

7.5.2. United Arab Emirates

7.5.3. Rest of Middle East and Africa

7.6. Asia-Pacific

7.6.1. China

7.6.2. India

7.6.3. Japan

7.6.4. South Korea

7.6.5. Taiwan

7.6.6. Thailand

7.6.7. Indonesia

7.6.8. Rest of Asia-Pacific

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Market Share Analysis

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Competitive Dashboard

9. COMPANY PROFILES

9.1. Novartis AG

9.2. Sanofi

9.3. Amneal Pharmaceuticals LLC.

9.4. Dr. Reddy’s Laboratories

9.5. McKesson Medical-Surgical Inc.

9.6. Laurus Labs Ltd.

9.7. Lupin Pharmaceuticals, Inc.

9.8. Mylan N.V.

9.9. Apotex

Novartis AG

Sanofi

Amneal Pharmaceuticals LLC.

Dr. Reddy’s Laboratories

McKesson Medical-Surgical Inc.

Laurus Labs Ltd.

Lupin Pharmaceuticals, Inc.

Mylan N.V.

Apotex